Skip to main content

Table 1 Characteristics of the cases included

From: Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis

 

Argentina (n = 2491)

Brazil (n = 2620)

Chile (n = 3352)

Colombia (n = 2057)

LATAM (n = 10,520)

Spain (n = 18,272)

Turkey (n = 2035)

Total (n = 30,827)

Age (year)

55.0 (16.7)

59.1 (17.0)

55.7 (19.9)

68.7 (13.1)

58.9 (17.9)

54.5 (18.1)

56.0 (15.1)

56.1 (18.0)

Smoking habits

 Current smokers

583 (23.4)

338 (12.9)

665 (19.8)

90 (4.4)

1676 (15.9)

4307 (23.6)

631 (31.0)

6614 (21.5)

 Ex-smokers

1014 (40.7)

1509 (57.6)

1143 (34.1)

931 (45.3)

4597 (43.7)

6959 (38.1)

939 (46.1)

12,495 (40.5)

 Never smokers

894 (35.9)

773 (29.5)

1544 (46.1)

1036 (50.4)

4247 (40.4)

7006 (38.3)

465 (22.9)

11,719 (38.0)

Alpha1 antitrypsin available

62 (2.5)

270 (10.3)

96 (2.9)

11 (0.5)

439 (4.2)

5137 (28.1)

109 (5.4)

5685 (18.4)

Alpha1 antitrypsin (mg/dl)

77.1 (49.1)

95.7 (48.8)

94.3 (48.0)

57.8 (57.5)

91.8 (49.4)

94.1 (32.0)

74.6 (55.7)

93.5 (34.4)

FEV1 available

1834 (73.6)

1603 (61.2)

807 (24.1)

0 (0)

4244 (40.3)

10,612 (58.1)

391 (19.2)

15,247 (49.5)

FEV1 (%)

60.7 (17.3)

51.5 (21.5)

65.4 (22.8)

58.1 (20.8)

75.6 (23.9)

53.7 (18.8)

70.2 (24.4)

  1. Data expressed as mean (standard deviation) or as absolute (relative) frequencies depending on the nature of the variable